Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

September 10, 2019

TRANSIENT: Treatment Timing Inconsequential When STEMI Resolves Before Revascularization

News Conference News ESC 2019

TRANSIENT: Treatment Timing Inconsequential When STEMI Resolves Before Revascularization

September 09, 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31997-X/fulltext

News Conference News ESC 2019

Ten-Year SYNTAXES Results Fix Roles for CABG, PCI in Complex CAD

September 05, 2019

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

News Conference News ESC 2019

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

September 04, 2019

Transfer for Primary PCI Still Better Than Fibrinolysis After 16 Years: DANAMI-2

News Conference News ESC 2019

Transfer for Primary PCI Still Better Than Fibrinolysis After 16 Years: DANAMI-2

September 04, 2019

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

News Conference News ESC 2019

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

Yael L. Maxwell

September 03, 2019

Ruling Out MI Safe With 0/1-Hour High-Sensitivity Troponin: RAPID-TNT

News Conference News ESC 2019

Ruling Out MI Safe With 0/1-Hour High-Sensitivity Troponin: RAPID-TNT

Michael O'Riordan

September 03, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

One-year outcomes after ST elevation myocardial infarction

Presentation ESC 2019

One-year Outcomes After ST Elevation Myocardial Infarction

Presenter: Uwe Zeymer

September 01, 2019

Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5

News Conference News ESC 2019

Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5

September 01, 2019

CONDI-2/ERIC-PPCI Puts the Kibosh on Ischemic Conditioning in STEMI

News Conference News ESC 2019

CONDI-2/ERIC-PPCI Puts the Kibosh on Ischemic Conditioning in STEMI

Yael L. Maxwell

September 01, 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

COMPLETE Beats Culprit-Only PCI in Multivessel STEMI and Timing Doesn’t Matter

News Conference News ESC 2019

COMPLETE Beats Culprit-Only PCI in Multivessel STEMI and Timing Doesn’t Matter

Yael L. Maxwell

September 01, 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

News Conference News ESC 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

August 31, 2019

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

News Conference News ESC 2019

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

Michael O'Riordan

August 31, 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

News Conference News ESC 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Yael L. Maxwell

August 31, 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.